查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1776225

皮肤填充剂的全球市场:洞察，竞争情形，市场预测:2032年年

Dermal Fillers - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

2024年，真皮填充剂市场规模达62.3822亿美元。预计到2032年，该市场规模将达到116.9543亿美元，2025年至2032年的复合年增长率为8.25%。真皮填充剂的需求受多种关键因素驱动。首先，全球整容手术数量的增长主要源于人口老化、人们对保持年轻容貌的渴望以及美学意识的不断提升。其次，与传统手术相比，微创整形手术因其便利性、更短的恢復时间和更低的成本，正日益受到人们的青睐。最后，研发投入的不断增加以及真皮填充剂技术的持续创新，也进一步推动了市场的成长。综合来看，这些因素预计将在2025年至2032年的预测期内推动真皮填充剂市场大幅扩张。

真皮填充剂市场动态：

根据国际美容整形外科学会 (ISAPS, 2024) 的数据，2023年全球共进行了超过3500万例美容手术，包括手术和非手术。值得注意的是，脸部和头部手术显着成长，超过650万例，比前一年增长19.6%。到2022年，这一成长趋势将包括超过1,490万例手术和超过1,880万例非手术手术，凸显了全球对美容提升日益增长的需求。

真皮填充剂在此背景下发挥重要作用。填充剂通常与手术配合使用，作为初步增强，或作为术后的改良工具。例如，填充剂通常用于抚平疤痕、恢復脸部体积，以及在拉皮或隆鼻手术后提升脸部特征。这种整合进一步巩固了真皮填充剂作为美容医学领域补充和独立解决方案的重要性。

全球美容手术的兴起是真皮填充剂市场成长的主要驱动力。这一增长是由日益增长的美学意识、向微创治疗的转变以及全球范围内获得先进美容手术的管道的改善所推动的。 ISAPS 也指出了强化这一全球动能的区域趋势。

  • 巴西继续保持其美容手术领先国家的地位，已实施超过 300 万例手术。
  • 印度也是美容手术的领先国家之一，报告了 1,028,723 例美容手术，其中 496,931 例为非手术手术，其中很大一部分是真皮填充剂。
  • 美国国立卫生研究院 (2024) 进一步报告称，印度整形外科医生实施的非手术面部年轻化手术数量位居世界第二，每年实施的整容手术超过一百万例。仅在 2022 年，印度就记录了约 370,656 例整容手术，显示对手术和非手术手术的需求持续增长。
  • 在英国，根据英国美容整形外科医生协会 (2023) 的数据，2022 年英国实施了超过 31,057 例整容手术，进一步促进了全球市场的扩张。

为了满足日益增长的需求，行业领导者正在加强研发力度，以开发具有更高功效、更安全、更持久的下一代真皮填充剂。 2025年4月，Evolus宣布推出Evolysse™ Form和Evolysse™ Smooth两种可注射透明质酸(HA)凝胶，旨在抚平皱纹、恢復丰盈度，尤其适用于法令纹（从鼻翼到嘴角的皱纹）。

然而，真皮填充剂相关的併发症和安全问题，以及高昂的治疗费用，是限制真皮填充剂市场成长的一些主要限制因素。

真皮填充剂市场区隔分析：

在真皮填充剂材料领域，透明质酸 (HA) 预计将在 2024 年占据最大的市场占有率。透明质酸 (HA) 在真皮填充剂市场中的成长受到多种关键因素的推动，包括 HA 基填充剂的日益普及、全球美容手术数量的增长，以及该类别的广泛益处和应用。

根据国际美容整形外科学会 (ISAPS, 2023) 的数据，2023 年全球进行了超过 5,564,866 例非手术美容手术，包括使用透明质酸填充剂的手术，高于 2022 年的 4,312,037 例。这一稳定成长主要得益于可支配收入的提高、人们对美容医疗趋势的认知度不断提升，以及对外表的日益关注，尤其是在城市居民和千禧世代中。

透明质酸填充剂的主要优点之一是透明质酸是人体内天然存在的物质，可显着降低过敏反应的风险。这些填充剂以其恢復脸部丰盈度、滋润肌肤、抚平皱纹和提升脸部轮廓的功效而闻名。玻尿酸填充剂与肌肤无缝融合，带来自然的外观和触感，深受寻求精緻而有效焕肤的患者青睐。

玻尿酸填充剂的另一个优点在于其效果立竿见影。注射后，这些填充剂能够快速补充体积，减少皱纹，并带来显着的美容效果，且无需长时间的恢復期。这种即时效果尤其吸引那些寻求快速、非侵入性改善以适应社交或职业场合的患者。此外，透明质酸填充剂的可逆性是其显着特点，可增强患者信心并增强医师的控制力。如果出现不满意或副作用，可以使用一种名为透明质酸酶的酵素安全地溶解填充剂，从而进一步提高治疗的安全性和灵活性。

持续的产品创新和行业领导者的监管审批也为该领域的成长提供了支持。例如，2023年5月，艾伯维（AbbVie）旗下公司艾尔建美学（Allergan Aesthetics）宣布美国FDA批准SKINVIVE™联合JUVEDERM®，这是一种新型透明质酸皮内注射微滴注射剂，旨在改善21岁及以上成年人的皮肤光滑度。 SKINVIVE™是美国首个也是唯一一个基于透明质酸（HA）的同类疗法，在最佳治疗条件下，疗效可持续长达六个月。

上述因素可能会推动这一细分市场的发展，并最终推动全球真皮填充剂市场的发展。

预计到2024年，北美将在真皮填充剂市场占据最大占有率，这主要得益于几个关键因素。这种区域主导地位主要归因于人口老化和人们对保持年轻外观的渴望日益增长，导緻美容手术数量不断增加。此外，对微创美容治疗日益增长的需求以及完善的医疗基础设施也显着促进了市场成长。人们对美容手术的认知度不断提高和广泛接受度也进一步支撑了这一趋势。此外，市场领先公司批准并推出的众多产品也巩固了北美的地位。综合来看，这些因素预计将在2025年至2032年的预测期内保持北美在真皮填充剂市场的领先地位。

根据国际美容整形外科学会（ISAPS，2023）的数据，美国在美容手术数量方面位居世界首位，共进行了6,196,701例手术，其中包括4,405,599例非手术美容治疗。在这些非手术手术中，84,817例使用了羟基磷灰石钙基填充剂，712,225例使用了透明质酸（HA）真皮填充剂。此外，美国整形外科医师协会 (2023) 报告称，2023 年美国共进行了超过 950 万例整形手术。

美容手术数量的增加是该地区真皮填充剂市场成长的关键驱动力。这一增长反映了对非手术、微创治疗日益增长的需求，这些治疗能够快速见效且恢復期最短。推动这一增长的因素包括：人们的认知度不断提高、美容整形的广泛接受度以及老龄化人口寻求保持年轻容貌的有效解决方案。

此外，主要市场参与者正在加强研发力度，以推出并商业化满足当地需求的先进真皮填充剂产品。例如，2023 年 6 月，高德美 (Galderma) 宣布美国食品药物管理局 (FDA) 批准 Restylane® Eyelight，该产品专为治疗 21 岁及以上成年人的眼底凹陷（黑眼圈）而设计。该产品是美国首款也是唯一一款采用NASHA®技术配製的透明质酸（HA）真皮填充剂，旨在解决眼底体积减少问题，并实现自然的眼部效果。

同样，2022年2月，艾伯维（AbbVie）旗下子公司Allergan Aesthetics宣布FDA批准JUVEDERM® VOLBELLA® XC用于治疗21岁及以上成年人的眶下窝。这款多功能填充剂还可用于丰唇和矫正口周皱纹，透过缩小眼底凹陷来改善整体脸部美观。

总而言之，越来越多的美容手术和策略性产品的推出正在推动北美对真皮填充剂的需求，以巩固其在全球真皮填充剂市场领先地位。

真皮填充剂市场的主要公司

真皮填充剂市场的主要参与者包括 AbbVie Inc.、Galderma、Merz Pharma、Tiger BioSciences、Teoxane SA、Crown Laboratories, Inc.、Prollenium Medical Technologies, Inc.、Johnson & Johnson Services, Inc.、Anika Therapeutics, Inc.、Fillmed、VIVACY LaboratorIinal Inc.、Anika Therapeutics, Inc。 Inc.、Symatese、LG Chem、KORU Pharma Co., Ltd. 和 BIOPLUS CO., Ltd.。

真皮填充剂市场的最新发展：

  • 2025 年 2 月，全球领先的皮肤护理创新公司－私人企业 Crown Laboratories, Inc. 宣布成功收购 Revance Therapeutics。公司是一家专注于真皮填充剂的先锋生物技术公司。此次收购显着增强了 Crown 的产品组合，并扩大了其在真皮填充剂市场的全球影响力，尤其体现在 RHA Redensity™ 以及一系列基于 RHA®2、RHA®3 和 RHA®4 的真皮填充剂上。
  • 2024 年 10 月，AbbVie 收购了 Revance Therapeutics, Inc。.Illergan Aesthetics 宣布在全美推出用于治疗太阳穴凹陷的 JUVEDERM® VOLUMA® XC。这款透明质酸 (HA) 填充剂已获批用于治疗 21 岁及以上成年人的中度至重度太阳穴凹陷。作为备受患者和医疗保健提供者青睐的领先 HA 真皮填充剂品牌，JUVEDERM® 填充剂系列现已提供最广泛的治疗适应症，帮助患者实现其美学目标。
  • 2022 年 10 月，Prollenium Medical Technologies Inc. 完成了对 Softfill® 的收购，Softfill® 是一个以先进的微型套管和创新化妆品而闻名的法国先锋品牌。透过此次策略性收购，Prollenium 透过引入透明质酸基真皮填充剂品牌 Revanesse® 来扩展其产品组合，从而巩固了其在全球真皮填充剂市场的地位，进一步增强了其提供尖端美学解决方案的能力。

真皮填充剂市场研究报告重点

  • 目前真皮填充剂市场规模分析（2024 年）及八年市场预测（2025-2032 年）
  • 过去三年主要产品/技术开发、併购、合作及合资企业
  • 主导真皮填充剂市场的主要公司
  • 真皮填充剂市场中其他竞争对手面临的各种机会
  • 2024 年主要细分市场及其未来前景 2032 年这些细分市场的表现
  • 目前真皮填充剂市场中表现最佳的地区和国家
  • 未来公司应关注真皮填充剂市场成长机会的地区和国家

真皮填充剂市场常见问题

1.真皮填充剂

  • 真皮填充剂是一种可注射的物质，用于美容医学，以恢復肌肤体积、抚平皱纹和细纹，并提升脸部轮廓。它们是一种常见的非手术美容疗法，旨在透过填充因衰老、遗传或环境因素而失去体积和弹性的部位，使脸部和其他身体部位恢復活力。

2. 真皮填充剂市场

  • 预计2024年真皮填充剂市值将达到62.3822亿美元，到2032年将达到116.9543亿美元，在2025年至2032年的预测期内，复合年增长率为8.25%。

3.真皮填充剂市场的驱动因素

  • 真皮填充剂的需求受到关键驱动因素的推动。全球整容手术数量的增长与老龄化社会密切相关，这源于人们日益增强的美学意识以及对保持年轻容貌的渴望。此外，人们越来越倾向于微创治疗，因为与传统手术相比，微创治疗具有便利、恢復时间短、成本效益高等优势。此外，持续的研发投入和真皮填充剂的持续创新，也促进了安全性、有效性和使用寿命更高的先进产品的推出。预计这些趋势将在2025年至2032年的预测期内推动真皮填充剂市场显着成长。

4.真皮填充剂市场的主要参与者

  • 真皮填充剂市场的主要参与者包括AbbVie Inc.，Galderma，Merz Pharma，Tiger BioSciences，Teoxane SA，Crown Laboratories, Inc.，Prollenium Medical Technologies, Inc，Johnson &Johnson Services, Inc.，Anika Therapeutics, Inc.，Fillmed，VIVACY Laboratories，Sinclair，Medytox，HUGEL, Inc.，Ipsen Pharma，Evolus, Inc.，Symatese，LG Chem，KORU Pharma Co.LTD.，BIOPLUS 有CO.LTD.等。

5. 真皮填充剂市场最大占有率的地区

  • 预计到 2024 年，北美将在真皮填充剂市场占据最大占有率，这主要受几个关键因素的影响。这种区域主导地位主要归因于人口老化和保持年轻外观的愿望推动了美容手术数量的增长。此外，对微创美容疗程的需求不断增长以及完善的医疗基础设施也显着促进了市场成长。人们对美容手术的认知度不断提高和广泛接受度进一步推动了这一趋势。此外，市场领先公司大量产品的核准和上市也巩固了北美市场的地位。综合来看，这些因素预计将在2025年至2032年的预测期内，维持北美在真皮填充剂市场的领先地位。

目录

第1章 皮肤填充剂市场报告的简介

第2章 皮肤填充剂市场摘要整理

第3章 竞争情形

第4章 法规分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第5章 皮肤填充剂市场主要原因分析

  • 真皮填充剂市场驱动因素
    • 全球化妆品市场成长手术
    • 微创美容手术需求不断成长
    • 真皮填充剂研发与创新投入不断增加
  • 真皮填充剂市场限制与课题
    • 真皮填充剂相关的併发症和安全问题
    • 治疗成本较高
  • 真皮填充剂市场的机遇
    • 更先进的可生物降解和可生物吸收填充剂的开发

第6章 皮肤填充剂市场上波特的五力分析

第7章 皮肤填充剂市场评估

  • 各产品类型
    • 生物分解性填充物
    • 非生物分解性填充剂
  • 不同材料
    • 玻尿酸(HA)
    • 烃基磷灰石钙(CaHA)
    • 多L乳酸(PLLA)
    • 聚甲基丙烯酸甲酯(PMMA)
    • 其他
  • 性别
    • 男性
    • 女性
  • 各终端用户
    • 医院
    • 皮肤科诊所
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 其他地区

第8章 皮肤填充剂市场企业与产品简介

  • AbbVie Inc.
  • Galderma
  • Merz Pharma
  • Tiger BioSciences
  • Teoxane SA
  • Crown Laboratories, Inc.
  • Prollenium Medical Technologies, Inc.
  • Johnson & Johnson Services, Inc.
  • Anika Therapeutics, Inc.
  • Fillmed
  • VIVACY Laboratories
  • Sinclair
  • Medytox
  • HUGEL, Inc.
  • Ipsen Pharma
  • Evolus, Inc.
  • Symatese
  • LG Chem
  • KORU Pharma Co., LTD.
  • BIOPLUS CO., LTD.

第9章 KOL的见解

第10章 计划方法

第11章 关于DelveInsight

第12章 免责声明和咨询方式

Product Code: DISR0218

Dermal Fillers Market by Product Type (Biodegradable Fillers and Non-Biodegradable Fillers), Material (Hyaluronic Acid (HA), Calcium hydroxylapatite (CaHA), Poly-L-lactic acid (PLLA), Polymethylmethacrylate (PMMA), and Others), Gender (Male and Female), End-User (Hospitals, Dermatology Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising number of cosmetic procedures performed globally and increasing product development and launches activities by key players.

The dermal fillers market was valued at USD 6,238.22 million in 2024, growing at a CAGR of 8.25% during the forecast period from 2025 to 2032 to reach USD 11,695.43 million by 2032. The demand for dermal fillers is driven by several key factors. Firstly, the rising number of cosmetic procedures performed globally is primarily attributed to the aging population and a growing desire to maintain a youthful appearance, alongside increasing aesthetic consciousness. Secondly, there is a strong shift towards minimally invasive cosmetic procedures due to their convenience, shorter recovery times, and lower costs compared to traditional surgeries. Lastly, increasing investments and continuous innovations in the research and development of dermal fillers are further propelling market growth. These factors collectively are expected to drive significant expansion in the dermal fillers market during the forecast period from 2025 to 2032.

Dermal Fillers Market Dynamics:

According to data from the International Society of Aesthetic Plastic Surgery (ISAPS, 2024), in 2023, more than 35 million aesthetic procedures, both surgical and non-surgical, were performed globally. Notably, face and head procedures experienced substantial growth, accounting for over 6.5 million procedures, marking a 19.6% increase from the previous year. In 2022, this upward trend included more than 14.9 million surgical and 18.8 million non-surgical procedures, underscoring the growing global demand for aesthetic enhancements.

Dermal fillers play a critical role in this landscape. They are often used alongside surgical procedures, either as a preliminary enhancement or a post-surgical refinement tool. For instance, fillers are commonly applied to smooth scars, restore facial volume, or enhance features following facelifts or rhinoplasty. This integration further solidifies the relevance of dermal fillers as a complementary and standalone solution in the field of aesthetic medicine.

The rising number of cosmetic procedures worldwide is a key driver of growth in the dermal fillers market. This surge is fueled by increasing aesthetic awareness, a shift toward minimally invasive treatments, and improved accessibility to advanced cosmetic procedures across the globe. ISAPS also highlighted regional trends that reinforce this global momentum. In 2023:

  • Brazil performed over 3 million aesthetic procedures, maintaining its position as one of the major countries in aesthetic procedures.
  • India reported 1,028,723 aesthetic procedures, of which 496,931 were non-surgical, a substantial portion involving dermal fillers, as one of the leading countries in cosmetic procedures.
  • The National Institutes of Health (2024) further reported that India ranked second globally country in the number of non-surgical facial rejuvenation procedures performed by plastic surgeons, with over 1 million aesthetic procedures conducted annually. In 2022 alone, the country recorded approximately 370,656 cosmetic surgeries, showcasing sustained demand across surgical and non-surgical procedures.
  • In the United Kingdom, data from the British Association of Aesthetic Plastic Surgeons (2023) showed that, in 2022, over 31,057 cosmetic procedures were conducted, further contributing to the global expansion of the market.

In response to rising demand, key industry players are intensifying R&D efforts to develop next-generation dermal fillers that offer improved efficacy, safety, and longevity. A notable example is Evolus, which in April 2025 announced the commercial launch of Evolysse(TM) Form and Evolysse(TM) Smooth, an injectable hyaluronic acid (HA) gels designed to smooth wrinkles and restore volume, particularly in areas such as the nasolabial folds (lines running from the nose to the corners of the mouth).

However, the complications and safety concerns associated with dermal fillers and high treatment cost, among others are some of the key constraints that may limit the growth of the dermal fillers market.

Dermal Fillers Market Segment Analysis:

Dermal Fillers Market by Product Type (Biodegradable Fillers and Non-Biodegradable Fillers), Material (Hyaluronic Acid (HA), Calcium hydroxylapatite (CaHA), Poly-L-lactic acid (PLLA), Polymethylmethacrylate (PMMA), and Others), Gender (Male and Female), End-User (Hospitals, Dermatology Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the material segment of the dermal fillers market, the hyaluronic acid (HA) category is estimated to account for the largest market share in 2024. The growth of the hyaluronic acid (HA) segment within the dermal fillers market is being propelled by several key factors, including the increasing adoption of HA-based fillers, the rising number of aesthetic procedures worldwide, and the wide range of benefits and applications associated with this category.

According to the International Society of Aesthetic Plastic Surgery (ISAPS, 2023), over 5,564,866 non-surgical cosmetic procedures involving hyaluronic acid-based dermal fillers were performed globally in 2023, up from 4,312,037 procedures in 2022. This steady upward trend is largely driven by growing disposable incomes, heightened awareness of cosmetic treatments, and an increasing focus on personal appearance, particularly among urban and millennial populations.

One of the primary advantages of HA-based fillers is that hyaluronic acid is a naturally occurring substance in the body, which significantly reduces the risk of allergic reactions. These fillers are well-known for their ability to restore facial volume, hydrate the skin, smooth wrinkles, and enhance facial contours. HA fillers integrate seamlessly with the skin, delivering a natural look and feel that appeals to patients seeking subtle yet effective rejuvenation.

Another important benefit of HA fillers is their capacity to provide immediate visible results. Upon injection, these fillers quickly replenish volume and reduce wrinkles, offering noticeable cosmetic improvements without extended downtime. This instant gratification is especially attractive to patients who desire quick, non-invasive enhancements for social or professional occasions. Furthermore, the reversibility of HA fillers is a standout feature that enhances patient confidence and physician control. In cases of dissatisfaction or adverse reactions, the filler can be safely dissolved using an enzyme called hyaluronidase, providing an added layer of safety and flexibility in treatment.

The segment's growth is also supported by continuous product innovations and regulatory approvals from leading industry players. For example, in May 2023, Allergan Aesthetics, an AbbVie company, announced the U.S. FDA approval of SKINVIVE(TM) by JUVEDERM(R), a novel hyaluronic acid intradermal microdroplet injection designed to improve skin smoothness in adults over 21. SKINVIVE(TM) is the first and only HA-based treatment of its kind available in the U.S., offering results that can last up to six months with optimal treatment.

Thus, the factors mentioned above are likely to boost the market segment and thereby increase the overall market of dermal fillers across the globe.

North America is expected to dominate the overall dermal fillers market:

North America is projected to hold the largest share of the dermal fillers market in 2024, driven by several key factors. This regional dominance can be primarily attributed to the rising number of cosmetic procedures performed, fueled by an aging population and an increasing desire to maintain a youthful appearance. Additionally, the growing demand for minimally invasive cosmetic treatments, coupled with a well-established healthcare infrastructure, has significantly contributed to market growth. Increased awareness and widespread acceptance of aesthetic procedures further support this trend. Moreover, numerous product approvals and new launches by leading market players are strengthening North America's position. Collectively, these factors are expected to sustain North America's leadership in the dermal fillers market throughout the forecast period from 2025 to 2032.

According to data from the International Society of Aesthetic Plastic Surgery (ISAPS, 2023), the United States led the world in the number of aesthetic procedures performed, with 6,196,701 total procedures, including 4,405,599 non-surgical cosmetic treatments. Among these non-surgical procedures, 84,817 involved Calcium Hydroxylapatite-based fillers, while 712,225 utilized hyaluronic acid (HA) dermal fillers. Additionally, the American Society of Plastic Surgeons (2023) reported that over 9.5 million plastic surgeries were performed in the U.S. in 2023.

The rising volume of aesthetic procedures is a significant driver of the dermal fillers market growth in the region. This increase reflects growing demand for non-surgical, minimally invasive treatments that offer quick results and minimal downtime. The surge is fueled by heightened awareness, broader acceptance of cosmetic enhancements, and an expanding aging population seeking effective solutions for maintaining a youthful appearance.

Furthermore, key market players are intensifying their research and development efforts to introduce and commercialize advanced dermal filler products tailored to meet regional needs. For example, in June 2023, Galderma announced the U.S. Food and Drug Administration (FDA) approval of Restylane(R) Eyelight, designed specifically for the treatment of under-eye hollows (dark shadows) in adults over 21. This product is the first and only HA dermal filler in the U.S. formulated with NASHA(R) Technology to address volume loss under the eyes, delivering natural-looking results.

Similarly, in February 2022, Allergan Aesthetics, an AbbVie company, announced FDA approval for JUVEDERM(R) VOLBELLA(R) XC to treat infraorbital hollows in adults over 21. This versatile filler is also used for lip augmentation and correction of perioral lines, enhancing overall facial aesthetics by improving the appearance of under-eye hollows.

Collectively, the increasing volume of cosmetic procedures combined with strategic product launches is propelling the demand for dermal fillers in North America, solidifying its position as a leading region in the global dermal fillers market.

Dermal Fillers Market Key Players:

Some of the key market players operating in the dermal fillers market include AbbVie Inc., Galderma, Merz Pharma, Tiger BioSciences, Teoxane SA, Crown Laboratories, Inc., Prollenium Medical Technologies, Inc., Johnson & Johnson Services, Inc., Anika Therapeutics, Inc., Fillmed, VIVACY Laboratories, Sinclair, Medytox, HUGEL, Inc., Ipsen Pharma, Evolus, Inc., Symatese, LG Chem, KORU Pharma Co., LTD., BIOPLUS CO., LTD., and others.

Recent Developmental Activities in the Dermal Fillers Market:

  • In February 2025, Crown Laboratories, Inc., a privately held global leader in skincare innovation, announced the successful acquisition of Revance Therapeutics, Inc., a pioneering biotechnology company specializing in dermal fillers. Through this acquisition, Crown significantly enhanced its product portfolio and expanded its global presence in the dermal fillers market, particularly with RHA Redensity(TM) and its range of RHA(R) 2, RHA(R) 3, and RHA(R) 4 based dermal fillers.
  • In October 2024, Allergan Aesthetics, an AbbVie company, announced the national availability of JUVEDERM(R) VOLUMA(R) XC for the treatment of temple hollowing. This hyaluronic acid (HA) filler is approved for addressing moderate to severe temple hollowing in adults over 21. As the leading HA dermal filler brand preferred by both patients and providers, the JUVEDERM(R) Collection of Fillers now offers the broadest range of treatment indications to help patients achieve their aesthetic goals.
  • In October 2022, Prollenium Medical Technologies Inc. completed the acquisition of SoftFil(R), a pioneering French brand known for its advanced micro-cannulas and innovative cosmetic products. Through this strategic acquisition, Prollenium strengthened its position in the global dermal fillers market by expanding its portfolio with Revanesse(R), a brand of hyaluronic acid-based dermal fillers, further enhancing its capabilities in delivering cutting-edge aesthetic solutions.

Key takeaways from the dermal fillers market report study

  • Market size analysis for current dermal fillers market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the dermal fillers market.
  • Various opportunities available for the other competitors in the dermal fillers market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current dermal fillers market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for dermal fillers market growth in the coming future?

Target audience who can benefit from this dermal fillers market report study

  • Dermal filler product providers
  • Research organizations and consulting companies
  • Dermal fillers-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in dermal fillers
  • Various end-users who want to know more about the dermal fillers market and the latest technological developments in the dermal fillers market.

Frequently Asked Questions for the Dermal Fillers Market:

1. What are dermal fillers?

  • Dermal fillers are injectable substances used in aesthetic medicine to restore volume, smooth out wrinkles and fine lines, and enhance facial contours. They are a popular non-surgical cosmetic treatment designed to rejuvenate the face and other areas by filling in areas that have lost volume or elasticity due to aging, genetics, or environmental factors.

2. What is the market for dermal fillers?

  • The dermal fillers market was valued at USD 6,238.22 million in 2024, growing at a CAGR of 8.25% during the forecast period from 2025 to 2032 to reach USD 11,695.43 million by 2032.

3. What are the drivers for the dermal fillers market?

  • The demand for dermal fillers is being fuelled by key drivers. The growing number of cosmetic procedures worldwide is closely linked to an aging population and a heightened desire among individuals to preserve a youthful appearance, supported by rising aesthetic awareness. Further, there is an increasing preference for minimally invasive treatments that offer the benefits of convenience, reduced recovery time, and cost-effectiveness compared to traditional surgical options. In addition, sustained investment and ongoing innovation in dermal filler research and development are contributing to the introduction of advanced products with improved safety, efficacy, and longevity. Together, these trends are expected to drive substantial growth in the dermal fillers market over the forecast period from 2025 to 2032.

4. Who are the key players operating in the dermal fillers market?

  • Some of the key market players operating in the dermal fillers market include AbbVie Inc., Galderma, Merz Pharma, Tiger BioSciences, Teoxane SA, Crown Laboratories, Inc., Prollenium Medical Technologies, Inc., Johnson & Johnson Services, Inc., Anika Therapeutics, Inc., Fillmed, VIVACY Laboratories, Sinclair, Medytox, HUGEL, Inc., Ipsen Pharma, Evolus, Inc., Symatese, LG Chem, KORU Pharma Co., LTD., BIOPLUS CO., LTD., and others.

5. Which region has the highest share in the dermal fillers market?

  • North America is projected to hold the largest share of the dermal fillers market in 2024, driven by several key factors. This regional dominance is primarily attributed to the rising number of cosmetic procedures performed, fueled by an aging population and an increasing desire to maintain a youthful appearance. Additionally, the growing demand for minimally invasive cosmetic treatments, coupled with a well-established healthcare infrastructure, has significantly contributed to market growth. Increased awareness and widespread acceptance of aesthetic procedures further support this trend. Moreover, numerous product approvals and new launches by leading market players are strengthening North America's position. Collectively, these factors are expected to sustain North America's leadership in the dermal fillers market throughout the forecast period from 2025 to 2032.

Table of Contents

1. Dermal Fillers Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Dermal Fillers Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Dermal Fillers Market Key Factors Analysis

  • 5.1. Dermal Fillers Market Drivers
    • 5.1.1. The rising number of cosmetic procedures performed globally
    • 5.1.2. The increasing demand for minimally invasive cosmetic procedures
    • 5.1.3. Increasing investments and innovations in the research and development of dermal fillers
  • 5.2. Dermal Fillers Market Restraints and Challenges
    • 5.2.1. Complications and safety concerns associated with dermal fillers
    • 5.2.2. High treatment cost
  • 5.3. Dermal Fillers Market Opportunity
    • 5.3.1. Development of more advanced biodegradable and bioresorbable fillers

6. Dermal Fillers Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Dermal Fillers Market Assessment

  • 7.1. By Product Type
    • 7.1.1. Biodegradable Fillers
    • 7.1.2. Non-Biodegradable Fillers
  • 7.2. By Material
    • 7.2.1. Hyaluronic Acid (HA)
    • 7.2.2. Calcium hydroxylapatite (CaHA)
    • 7.2.3. Poly-L-lactic acid (PLLA)
    • 7.2.4. Polymethylmethacrylate (PMMA)
    • 7.2.5. Others
  • 7.3. By Gender
    • 7.3.1. Male
    • 7.3.2. Female
  • 7.4. By End-User
    • 7.4.1. Hospitals
    • 7.4.2. Dermatology Clinics
    • 7.4.3. Others
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.1.2. Canada Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.1.3. Mexico Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.2. Europe
      • 7.5.2.1. France Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.2.2. Germany Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.2.3. United Kingdom Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.2.4. Italy Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.2.5. Spain Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.2.6. Rest of Europe Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.3.2. Japan Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.3.3. India Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.3.4. Australia Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.3.5. South Korea Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.3.6. Rest of Asia-Pacific Dermal Fillers Market Size in USD million (2022-2032)
    • 7.5.4. Rest of the World (RoW)
      • 7.5.4.1. Middle East Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.4.2. Africa Dermal Fillers Market Size in USD million (2022-2032)
      • 7.5.4.3. South America Dermal Fillers Market Size In USD Million (2022-2032)

8. Dermal Fillers Market Company and Product Profiles

  • 8.1. AbbVie Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Galderma
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Merz Pharma
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Tiger BioSciences
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Teoxane SA
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Crown Laboratories, Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Prollenium Medical Technologies, Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Johnson & Johnson Services, Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Anika Therapeutics, Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Fillmed
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. VIVACY Laboratories
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Sinclair
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Medytox
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. HUGEL, Inc.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Ipsen Pharma
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Evolus, Inc.
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Symatese
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. LG Chem
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. KORU Pharma Co., LTD.
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. BIOPLUS CO., LTD.
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Dermal Fillers Market in Global (2022-2032)
  • Table 3: Dermal Fillers Market in Global by Product Type (2022-2032)
  • Table 4: Dermal Fillers Market in Global by Material (2022-2032)
  • Table 5: Dermal Fillers Market in Global by Gender (2022-2032)
  • Table 6: Dermal Fillers Market in Global by End-User (2022-2032)
  • Table 7: Dermal Fillers Market in Global by Geography (2022-2032)
  • Table 8: Dermal Fillers Market in North America (2022-2032)
  • Table 9: Dermal Fillers Market in the United States (2022-2032)
  • Table 10: Dermal Fillers Market in Canada (2022-2032)
  • Table 11: Dermal Fillers Market in Mexico (2022-2032)
  • Table 12: Dermal Fillers Market in Europe (2022-2032)
  • Table 13: Dermal Fillers Market in France (2022-2032)
  • Table 14: Dermal Fillers Market in Germany (2022-2032)
  • Table 15: Dermal Fillers Market in United Kingdom (2022-2032)
  • Table 16: Dermal Fillers Market in Italy (2022-2032)
  • Table 17: Dermal Fillers Market in Spain (2022-2032)
  • Table 18: Dermal Fillers Market in the Rest of Europe (2022-2032)
  • Table 19: Dermal Fillers Market in Asia-Pacific (2022-2032)
  • Table 20: Dermal Fillers Market in China (2022-2032)
  • Table 21: Dermal Fillers Market in Japan (2022-2032)
  • Table 22: Dermal Fillers Market in India (2022-2032)
  • Table 23: Dermal Fillers Market in Australia (2022-2032)
  • Table 24: Dermal Fillers Market in South Korea (2022-2032)
  • Table 25: Dermal Fillers Market in Rest of Asia-Pacific (2022-2032)
  • Table 26: Dermal Fillers Market in the Rest of the World (2022-2032)
  • Table 27: Dermal Fillers Market in the Middle East (2022-2032)
  • Table 28: Dermal Fillers Market in Africa (2022-2032)
  • Table 29: Dermal Fillers Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Dermal Fillers Market in Global (2022-2032)
  • Figure 3: Dermal Fillers Market in Global by Product Type (2022-2032)
  • Figure 4: Dermal Fillers Market in Global by Material (2022-2032)
  • Figure 5: Dermal Fillers Market in Global by Gender (2022-2032)
  • Figure 6: Dermal Fillers Market in Global by End-User (2022-2032)
  • Figure 7: Dermal Fillers Market in Global by Geography (2022-2032)
  • Figure 8: Dermal Fillers Market in North America (2022-2032)
  • Figure 9: Dermal Fillers Market in the United States (2022-2032)
  • Figure 10: Dermal Fillers Market in Canada (2022-2032)
  • Figure 11: Dermal Fillers Market in Mexico (2022-2032)
  • Figure 12: Dermal Fillers Market in Europe (2022-2032)
  • Figure 13: Dermal Fillers Market in France (2022-2032)
  • Figure 14: Dermal Fillers Market in Germany (2022-2032)
  • Figure 15: Dermal Fillers Market in United Kingdom (2022-2032)
  • Figure 16: Dermal Fillers Market in Italy (2022-2032)
  • Figure 17: Dermal Fillers Market in Spain (2022-2032)
  • Figure 18: Dermal Fillers Market in the Rest of Europe (2022-2032)
  • Figure 19: Dermal Fillers Market in Asia-Pacific (2022-2032)
  • Figure 20: Dermal Fillers Market in China (2022-2032)
  • Figure 21: Dermal Fillers Market in Japan (2022-2032)
  • Figure 22: Dermal Fillers Market in India (2022-2032)
  • Figure 23: Dermal Fillers Market in Australia (2022-2032)
  • Figure 24: Dermal Fillers Market in South Korea (2022-2032)
  • Figure 25: Dermal Fillers Market in Rest of Asia-Pacific (2022-2032)
  • Figure 26: Dermal Fillers Market in the Rest of the World (2022-2032)
  • Figure 27: Dermal Fillers Market in the Middle East (2022-2032)
  • Figure 28: Dermal Fillers Market in Africa (2022-2032)
  • Figure 29: Dermal Fillers Market in South America (2022-2032)
  • Figure 30: Market Drivers
  • Figure 31: Market Barriers
  • Figure 32: Marker Opportunities
  • Figure 33: PORTER'S Five Force Analysis